Healthcare companies by risk reading
Healthcare companies by risk reading: 1,695 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 21 October 2026.
Composite readings for 14,899 companies, recomputed 21 October 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Auna S.A. - Cls A AUNA | 30 | Normal | Healthcare | Luxembourg | 5 / 6 | $398M |
| Tilray Brands Inc TLRY | 64 | Stretched | Healthcare | Canada | 5 / 6 | $397M |
| Shanghai Bao Pharmaceuticals Co., Ltd. 2659.HK | 53 | Elevated | Healthcare | China | 5 / 6 | $395M |
| Allergy Therapeutics AGY | 79 | Stretched | Healthcare | United Kingdom | 5 / 6 | $395M |
| Computer Programs & Systems Inc TBRG | 48 | Elevated | Healthcare | United States | 5 / 6 | $394M |
| Avacta Group PLC AVCT | 69 | Stretched | Healthcare | United Kingdom | 5 / 6 | $393M |
| Orthofix Medical Inc OFIX | 64 | Stretched | Healthcare | United States | 6 / 6 | $391M |
| Heartseed Inc. 219A.T | 11 | Contained | Healthcare | Japan | 5 / 6 | $390M |
| Community Health Systems Inc CYH | 47 | Elevated | Healthcare | United States | 5 / 6 | $389M |
| Regenxbio Inc RGNX | 60 | Stretched | Healthcare | United States | 6 / 6 | $387M |
| Formycon AG FYB | 75 | Stretched | Healthcare | Germany | 5 / 6 | $385M |
| NIOX Group PLC NIOX | 21 | Normal | Healthcare | United Kingdom | 5 / 6 | $381M |
| Laekna, Inc. 2105.HK | 69 | Stretched | Healthcare | China | 4 / 6 | $380M |
| Shin Nippon Biomedical Laboratories, Ltd. 2395.T | 45 | Elevated | Healthcare | Japan | 5 / 6 | $375M |
| Simulations Plus Inc SLP | 50 | Elevated | Healthcare | United States | 5 / 6 | $374M |
| China Resources Medical Holdings Company Limited 1515.HK | 39 | Normal | Healthcare | China | 5 / 6 | $374M |
| Yidu Tech Inc. 2158.HK | 61 | Stretched | Healthcare | China | 5 / 6 | $373M |
| Australian Clinical Labs Limited ACL.AX | 49 | Elevated | Healthcare | Australia | 4 / 6 | $373M |
| Peijia Medical Limited 9996.HK | 47 | Elevated | Healthcare | China | 5 / 6 | $372M |
| MultiPlan Corp - Class A CTEV | 64 | Stretched | Healthcare | United States | 4 / 6 | $372M |
| Carlsmed Inc CARL | 53 | Elevated | Healthcare | United States | 6 / 6 | $372M |
| Editas Medicine Inc EDIT | 55 | Elevated | Healthcare | United States | 4 / 6 | $372M |
| Boiron SA BOI | 46 | Elevated | Healthcare | France | 5 / 6 | $370M |
| Medtide Inc. 3880.HK | 23 | Normal | Healthcare | China | 5 / 6 | $369M |
| Scribe Therapeutics Inc. SCTX | 61 | Stretched | Healthcare | United States | 5 / 6 | $367M |
| ASKA Pharmaceutical Holdings Co.,Ltd. 4886.T | 37 | Normal | Healthcare | Japan | 5 / 6 | $367M |
| Viemed Healthcare Inc VMD | 35 | Normal | Healthcare | United States | 6 / 6 | $365M |
| Alpha Teknova Inc TKNO | 65 | Stretched | Healthcare | United States | 6 / 6 | $365M |
| Jenscare Scientific Co., Ltd. 9877.HK | 68 | Stretched | Healthcare | China | 4 / 6 | $361M |
| Kitazato Corporation 368A.T | 35 | Normal | Healthcare | Japan | 4 / 6 | $361M |
| ALLERGY THER. PLC LS-001 HHU | 80 | Acute | Healthcare | United Kingdom | 5 / 6 | $360M |
| Viva Biotech Holdings 1873.HK | 51 | Elevated | Healthcare | China | 5 / 6 | $360M |
| Fennec Pharmaceuticals Inc FENC | 48 | Elevated | Healthcare | United States | 4 / 6 | $360M |
| Optima Health plc OPT | 22 | Normal | Healthcare | United Kingdom | 5 / 6 | $358M |
| IVF Hartmann Holding AG VBSN | 34 | Normal | Healthcare | Switzerland | 5 / 6 | $357M |
| C4 Therapeutics Inc CCCC | 48 | Elevated | Healthcare | United States | 5 / 6 | $355M |
| PureTech Health plc PRTC.L | 39 | Normal | Healthcare | United States | 5 / 6 | $353M |
| Cuorips Inc. 4894.T | 61 | Stretched | Healthcare | Japan | 4 / 6 | $352M |
| Embecta Corp EMBC | 50 | Elevated | Healthcare | United States | 5 / 6 | $352M |
| MicroTech Medical (Hangzhou) Co., Ltd. 2235.HK | 22 | Normal | Healthcare | China | 4 / 6 | $346M |
| Software Service, Inc. 3733.T | 25 | Normal | Healthcare | Japan | 4 / 6 | $345M |
| TAUNS Laboratories,Inc. 197A.T | 36 | Normal | Healthcare | Japan | 5 / 6 | $343M |
| Crescent Biopharma Inc CBIO | 55 | Elevated | Healthcare | United States | 4 / 6 | $343M |
| Orchestra BioMed Holdings Inc OBIO | 40 | Elevated | Healthcare | United States | 5 / 6 | $340M |
| Coltene Holding AG CLTN | 44 | Elevated | Healthcare | Switzerland | 5 / 6 | $334M |
| CapsoVision Inc CV | 51 | Elevated | Healthcare | United States | 6 / 6 | $334M |
| Japan Eyewear Holdings Co., Ltd. 5889.T | 20 | Normal | Healthcare | Japan | 5 / 6 | $333M |
| Enanta Pharmaceuticals Inc ENTA | 62 | Stretched | Healthcare | United States | 5 / 6 | $332M |
| Optima Health plc J3N | 24 | Normal | Healthcare | United Kingdom | 5 / 6 | $332M |
| CF PharmTech, Inc. 2652.HK | 46 | Elevated | Healthcare | China | 5 / 6 | $329M |
| Emergent Biosolutions Inc EBS | 58 | Elevated | Healthcare | United States | 5 / 6 | $326M |
| BioDlink International Company Limited 1875.HK | 66 | Stretched | Healthcare | China | 5 / 6 | $325M |
| Intermestic Inc. 262A.T | 32 | Normal | Healthcare | Japan | 5 / 6 | $318M |
| Zhejiang Taimei Medical Technology Co., Ltd. 2576.HK | 67 | Stretched | Healthcare | China | 5 / 6 | $318M |
| Ocuphire Pharma Inc IRD | 69 | Stretched | Healthcare | United States | 3 / 6 | $316M |
| Artrya Limited AYA.AX | 61 | Stretched | Healthcare | Australia | 3 / 6 | $314M |
| Integrated Diagnostics Holdings PLC IDHC | 15 | Contained | Healthcare | Jersey | 5 / 6 | $314M |
| Fuji Pharma Co., Ltd. 4554.T | 39 | Normal | Healthcare | Japan | 5 / 6 | $313M |
| 3-D Matrix, Ltd. 7777.T | 26 | Normal | Healthcare | Japan | 5 / 6 | $312M |
| Animalcare Group Plc ANCR | 40 | Elevated | Healthcare | United Kingdom | 5 / 6 | $309M |
| Semler Scientific Inc SMLR | 44 | Elevated | Healthcare | United States | 5 / 6 | $308M |
| Shanghai Pioneer Holding Ltd 1345.HK | 39 | Normal | Healthcare | China | 5 / 6 | $306M |
| Sanara MedTech Inc SMTI | 34 | Normal | Healthcare | United States | 5 / 6 | $305M |
| Canopy Growth Corporation CGC | 67 | Stretched | Healthcare | Canada | 5 / 6 | $303M |
| Oceania Healthcare Ltd OCA | 62 | Stretched | Healthcare | New Zealand | 4 / 6 | $303M |
| YSB Inc. 9885.HK | 40 | Elevated | Healthcare | China | 5 / 6 | $297M |
| Arcturus Therapeutics Holdings Inc ARCT | 80 | Acute | Healthcare | United States | 6 / 6 | $296M |
| Frontage Holdings Corporation 1521.HK | 45 | Elevated | Healthcare | United States | 5 / 6 | $295M |
| Mobia Medical, Inc. MOBI | 67 | Stretched | Healthcare | United States | 5 / 6 | $293M |
| Lavipharm S.A LAVI | 35 | Normal | Healthcare | Greece | 5 / 6 | $289M |
| Charm Care Corporation 6062.T | 34 | Normal | Healthcare | Japan | 5 / 6 | $289M |
| Jiangsu Recbio Technology Co., Ltd. 2179.HK | 80 | Acute | Healthcare | China | 4 / 6 | $287M |
| ProKidney Corp - Class A PROK | 53 | Elevated | Healthcare | United States | 5 / 6 | $287M |
| Eurobio Scientific SA ALERS | 46 | Elevated | Healthcare | France | 5 / 6 | $285M |
| CYBERDYNE Inc. 7779.T | 46 | Elevated | Healthcare | Japan | 5 / 6 | $284M |
| CLINUVEL PHARMAC.ADRS1 UR9A | 32 | Normal | Healthcare | Australia | 4 / 6 | $283M |
| LAVIPHARM S.A. NA EO 1 BXA0 | 36 | Normal | Healthcare | Greece | 5 / 6 | $282M |
| Santhera Pharmaceuticals Holding AG SANN | 53 | Elevated | Healthcare | Switzerland | 5 / 6 | $281M |
| Surrozen Inc SRZN | 70 | Stretched | Healthcare | United States | 5 / 6 | $280M |
| ClearPoint Neuro Inc CLPT | 69 | Stretched | Healthcare | United States | 4 / 6 | $280M |
| Tristel TSTL | 16 | Contained | Healthcare | United Kingdom | 5 / 6 | $279M |
| Elan Corporation 6099.T | 28 | Normal | Healthcare | Japan | 5 / 6 | $278M |
| Jiangxi Rimag Group Co., Ltd. 2522.HK | 43 | Elevated | Healthcare | China | 5 / 6 | $278M |
| Clinuvel Pharmaceuticals Limited UR9 | 32 | Normal | Healthcare | Australia | 4 / 6 | $277M |
| InfuSystem Holdings Inc INFU | 27 | Normal | Healthcare | United States | 5 / 6 | $274M |
| Anika Therapeutics Inc ANIK | 56 | Elevated | Healthcare | United States | 6 / 6 | $271M |
| Prelude Therapeutics Inc PRLD | 50 | Elevated | Healthcare | United States | 5 / 6 | $270M |
| Starpharma Holdings Ltd SPL | 51 | Elevated | Healthcare | Australia | 4 / 6 | $268M |
| LNA Sante SA LNA | 39 | Normal | Healthcare | France | 6 / 6 | $268M |
| Ocugen Inc OCGN | 60 | Stretched | Healthcare | United States | 5 / 6 | $267M |
| OneMedNet Corp ONMD | 56 | Elevated | Healthcare | United States | 5 / 6 | $267M |
| Clinuvel Pharmaceuticals Limited CUV.AX | 44 | Elevated | Healthcare | Australia | 4 / 6 | $267M |
| Century Therapeutics Inc IPSC | 43 | Elevated | Healthcare | United States | 4 / 6 | $265M |
| Rion Co., Ltd. 6823.T | 41 | Elevated | Healthcare | Japan | 4 / 6 | $265M |
| X4 Pharmaceuticals Inc XFOR | 48 | Elevated | Healthcare | United States | 5 / 6 | $264M |
| AFT Pharmaceuticals Limited AFP.AX | 37 | Normal | Healthcare | New Zealand | 4 / 6 | $264M |
| Agenus Inc AGEN | 71 | Stretched | Healthcare | United States | 6 / 6 | $263M |
| Mabpharm Limited 2181.HK | 35 | Normal | Healthcare | China | 5 / 6 | $263M |
| Value HR Co.,Ltd. 6078.T | 29 | Normal | Healthcare | Japan | 5 / 6 | $262M |
| VISEN Pharmaceuticals 2561.HK | 69 | Stretched | Healthcare | China | 4 / 6 | $257M |
By sector
Industrials 3,117Technology 2,425Consumer Cyclical 2,231Healthcare 1,695Consumer Defensive 1,055Basic Materials 1,055Real Estate 1,011Communication Services 956Energy 487Utilities 343Financial Services 90
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.